TABLE 3.
Therapy | No. of Patients | No. of CRs (%) |
---|---|---|
VAD/hyper-CVAD | 61 | 17 (28) |
Cytarabine combinations | 54 | 17 (32) |
Allogeneic bone marrow transplantation | 22 | 9 (41) |
Methotrexate-asparaginase combinations | 52 | 3 (6) |
Other combinations | 29 | 4 (14) |
Single agent | 70 | 3 (4) |
CRs indicates complete responses; VAD, vincristine, doxorubicin, and dexamethasone; hyper-CVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone.